CHAI was founded in 2002 with the transformational goal to help save the lives of millions of people living with HIV/AIDS in the developing world. By 2005, when CHAI began working on pediatric HIV/AIDS, children were being left behind at an astonishing rate: only one in 40 children in need was on treatment. Why were…

London, 30 November 2016 – UNITAID and the Clinton Health Access Initiative (CHAI) today announced a three-year project to speed the introduction of new, optimal HIV drugs, and make them more available and affordable.  The US$34 million investment is expected to be a boon for adults and children living with HIV who receive treatments that…

In a small village in rural east-central Uganda, baby Josephin is happily babbling to her mother Kevina and crawling around the yard. She has recovered well from a bout of bad diarrhea that she was suffering from just one day ago. Josephin is one of the lucky ones. She was able to access effective treatment…

CHAI supports national governments to expand high-quality care and treatment to people living with HIV/AIDS. CHAI negotiates reduced prices for antiretrovirals (ARVs) on behalf of members of its procurement consortium. See the 2016 CHAI ARV Reference Price List here.

Pneumonia is the leading cause of death for children globally, taking more lives annually than HIV, tuberculosis, and malaria combined. It is estimated that a child dies from pneumonia every 35 seconds. Pneumonia, a severe respiratory infection in which a child’s lungs fill with fluid, makes it difficult for them to absorb and exchange oxygen….

  A Neglected Disease in Africa Sub-Saharan Africa’s cancer burden is significant and growing. In 2012, there were an estimated 626,400 new cases of cancer and 447,700 deaths from cancer in Sub-Saharan Africa. The World Health Organization projects that by 2030, close to 1 million people will die of cancer each year in Sub-Saharan Africa….

Sixteen years ago, the 13th International AIDS Conference (IAS) convened in Durban, South Africa, to “break the silence” on the millions of preventable AIDS-related deaths occurring around the world. The summit was notable as it laid out the clear case that HIV causes AIDS, allowed people living with HIV/AIDS (PLWHA)’s voices to be heard, and…

CHAI’s ARV Market Report provides a global perspective on the ARV marketplace in low- and middle-income countries in 2015 and outlines CHAI’s expectations on how the market will evolve over the next five years. See the ARV Market Report here.

In Malawi, innovative models have been developed to optimize the efficiency of HIV service delivery in order to scale up access to treatment. In particular, three key models of differentiated care have emerged: multi-month prescriptions; fast-track drug refills; and community ART groups. In collaboration with the Ministry of Health of Malawi, CHAI conducted a mixed…

  Aurobindo Pharma Limited is pleased to announce the tentative approval of Dolutegravir 50mg from US Food & Drug Administration (USFDA) for the treatment of HIV. This important milestone marks the first FDA approval of a generic version of Dolutegravir (DTG), an integrase strand transfer inhibitor recommended for use in treatment-naïve patients by the US…